| Cash Flow | 2025-06-30 |
|---|---|
| Net loss | -153,815 |
| Prepaid expenses and other current assets | 1,487 |
| Accounts payable to related party | 1,027 |
| Accounts payable and accrued expenses | 204,904 |
| Loss on debt conversion | 0 |
| Change in fair value of derivative | 424,830 |
| Amortization of debt discount and deferred finance costs | 81,095 |
| Net cash provided by (used in) operating activities | -293,106 |
| Repaid to note holders | 0 |
| Repaid to related party/others | 0 |
| Proceeds from short term loans, others | 295,000 |
| Proceeds from sales of common stock | 0 |
| Proceeds from convertible debt | 0 |
| Proceeds from / (repayment to) private placement | 0 |
| Net cash provided by financing activities | 295,000 |
| Net increase (decrease) in cash | 1,894 |
Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics, Inc. (OTLC)